Aflibercept for the Treatment of Diabetic Macular Edema

Harkins, Keegan; Haschke, Mary; Diana, V.

doi:10.2217/imt.16.5

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, aflibercept is licensed in the USA, EU, Japan, Switzerland, and Australia for several different vascular retinal diseases, including DMO. 28…”

Section: Pacoresmentioning

confidence: 99%

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?

Yee

Sanjay

2017

EMJ Diabet

View full text Add to dashboard Cite

Over the last decade, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have been increasingly used in the management of various retinal diseases, especially diabetic macular oedema. Diabetic macular oedema is one of the leading causes of legal blindness among patients with diabetic retinopathy, meaning these patients are eligible for associated medical benefits. It is essential that diabetic macular oedema is managed with an effective and safe treatment for good long-term prognosis. Over the past decade, focal/grid laser photocoagulation has been the gold standard treatment. However, evidence supporting the superior clinical benefits and relative safety of anti-VEGF agents has driven a recent shift in treatment paradigm, favouring anti-VEGF over laser treatment. Previous studies involving systemic anti-VEGF treatment in cancers have identified an associated increased risk of arteriothrombotic events, such as myocardial infarction and stroke, which are potentially fatal. Hence, it is important to evaluate whether such risks, which will significantly alter the safety profile, persist with intravitreal administration. A comprehensive literature review was performed and concluded that no significant increase in risk of ocular or non-ocular adverse events, particularly arteriothrombotic events, were associated with anti-VEGF agents, predicting an overall favourable safety profile. A summary of some of the possible adverse events recorded in the various studies, albeit at relatively low rates, are also included. Additionally, it is briefly discussed how real-world concerns of cost and affordability can influence treatment choice, thereby affecting how clinical evidence is transferred into practice.

show abstract

“…Currently, aflibercept is licensed in the USA, EU, Japan, Switzerland, and Australia for several different vascular retinal diseases, including DMO. 28…”

Section: Pacoresmentioning

confidence: 99%

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?

Yee

Sanjay

2017

EMJ Diabet

View full text Add to dashboard Cite

show abstract

“…Furthermore, after the loading phase (five monthly injections), the prescribing information recommends an Aflibercept injection every two months, resulting in a reduced number of injections during the first year of follow-up [ 8 , 9 , 10 ]. Therefore, Aflibercept is currently considered one of the first line therapeutic approaches in DME [ 7 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Predictive Factors of Visual Outcome in Treatment-Naïve Diabetic Macular Edema: Preliminary Results from the Clinical Study “FOVEA”

Serra

Coscas

Boulet³

et al. 2023

JCM

View full text Add to dashboard Cite

Diabetic macular edema (DME) is a common cause of vision impairment in diabetic retinopathy. The aim of this study was to analyze the relationship between visual outcome and anatomic changes detected by traditional multimodal retinal imaging and optical coherence tomography angiography (OCTA) in DME eyes under treatment with Aflibercept. Methods: Sixty-six DME eyes of 62 patients under treatment with intravitreal Aflibercept and with one-year follow-up were enrolled. All participants underwent a full ophthalmic evaluation, including best correct visual acuity (BCVA) measurement, spectral-domain optical coherence tomography, fluorescein angiography and OCTA, both at baseline and final examination. Fractal OCTA analysis of the superficial and deep capillary plexus (SCP and DCP) was performed to estimate vascular perfusion density and lacunarity (LAC). Results: At the final examination, there was a significant improvement in terms of BCVA and central macular thickness (CMT). Furthermore, eyes with CMT <373 µm at baseline reached the higher BCVA at the last follow-up. Eyes with CMT ≥373 µm and DCP LAC <0.41 reached a higher final BCVA, if compared with eyes showing the same CMT but higher initial LAC. Conclusion: A 12-month treatment with intravitreal Aflibercept for DME resulted in significant visual and anatomic improvement. Multimodal retinal imaging, together with fractal OCTA analysis, may provide useful biomarkers, predictive of visual outcome in DME.

show abstract

Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis

Whiting

Pearce

Vansteenkiste

et al. 2020

Experimental Eye Research

View full text Add to dashboard Cite

Aflibercept for the Treatment of Diabetic Macular Edema

Cited by 5 publications

References 21 publications

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?

Predictive Factors of Visual Outcome in Treatment-Naïve Diabetic Macular Edema: Preliminary Results from the Clinical Study “FOVEA”

Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis

Contact Info

Product

Resources

About